WO2004082822A3 - Methods for isolating crystalline form i of 5-azacytidine - Google Patents

Methods for isolating crystalline form i of 5-azacytidine Download PDF

Info

Publication number
WO2004082822A3
WO2004082822A3 PCT/US2004/007896 US2004007896W WO2004082822A3 WO 2004082822 A3 WO2004082822 A3 WO 2004082822A3 US 2004007896 W US2004007896 W US 2004007896W WO 2004082822 A3 WO2004082822 A3 WO 2004082822A3
Authority
WO
WIPO (PCT)
Prior art keywords
azacytidine
crystalline form
methods
isolating crystalline
isolating
Prior art date
Application number
PCT/US2004/007896
Other languages
French (fr)
Other versions
WO2004082822A2 (en
Inventor
Dumitru Ionescu
Peter Blumbergs
Gary L Silvey
Original Assignee
Pharmion Corp
Ash Stevens Inc
Dumitru Ionescu
Peter Blumbergs
Gary L Silvey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004082822(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES04721078T priority Critical patent/ES2425474T3/en
Priority to AU2004222274A priority patent/AU2004222274B2/en
Priority to MXPA05009969A priority patent/MXPA05009969A/en
Priority to EP04721078.6A priority patent/EP1608634B1/en
Priority to CA002518973A priority patent/CA2518973A1/en
Application filed by Pharmion Corp, Ash Stevens Inc, Dumitru Ionescu, Peter Blumbergs, Gary L Silvey filed Critical Pharmion Corp
Priority to PL04721078T priority patent/PL1608634T3/en
Priority to SI200432065T priority patent/SI1608634T1/en
Priority to DK04721078.6T priority patent/DK1608634T3/en
Priority to JP2006507211A priority patent/JP4792550B2/en
Priority to BRPI0408506-0A priority patent/BRPI0408506A/en
Publication of WO2004082822A2 publication Critical patent/WO2004082822A2/en
Publication of WO2004082822A3 publication Critical patent/WO2004082822A3/en
Priority to AU2010241198A priority patent/AU2010241198B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Abstract

The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine.
PCT/US2004/007896 2003-03-17 2004-03-16 Methods for isolating crystalline form i of 5-azacytidine WO2004082822A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0408506-0A BRPI0408506A (en) 2003-03-17 2004-03-16 processes for isolation of crystalline form i from 5-azacytidine
SI200432065T SI1608634T1 (en) 2003-03-17 2004-03-16 Methods for isolating crystalline form i of 5-azacytidine
MXPA05009969A MXPA05009969A (en) 2003-03-17 2004-03-16 Methods for isolating crystalline form i of 5-azacytidine.
EP04721078.6A EP1608634B1 (en) 2003-03-17 2004-03-16 Methods for isolating crystalline form i of 5-azacytidine
CA002518973A CA2518973A1 (en) 2003-03-17 2004-03-16 Methods for isolating crystalline form i of 5-azacytidine
ES04721078T ES2425474T3 (en) 2003-03-17 2004-03-16 Methods for isolating the crystalline form I of 5-azacitidine
PL04721078T PL1608634T3 (en) 2003-03-17 2004-03-16 Methods for isolating crystalline form i of 5-azacytidine
AU2004222274A AU2004222274B2 (en) 2003-03-17 2004-03-16 Methods for isolating crystalline Form I of 5-azacytidine
DK04721078.6T DK1608634T3 (en) 2003-03-17 2004-03-16 PROCEDURES FOR INSULATING CRYSTALLINIC FORM OF 5-AZACYTIDINE
JP2006507211A JP4792550B2 (en) 2003-03-17 2004-03-16 Method for separating 5-azacytidine crystal form I
AU2010241198A AU2010241198B2 (en) 2003-03-17 2010-11-03 Methods for isolating crystalline Form I of 5-azacytidine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/390,530 2003-03-17
US10/390,530 US6943249B2 (en) 2003-03-17 2003-03-17 Methods for isolating crystalline Form I of 5-azacytidine

Publications (2)

Publication Number Publication Date
WO2004082822A2 WO2004082822A2 (en) 2004-09-30
WO2004082822A3 true WO2004082822A3 (en) 2005-07-07

Family

ID=32987551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007896 WO2004082822A2 (en) 2003-03-17 2004-03-16 Methods for isolating crystalline form i of 5-azacytidine

Country Status (16)

Country Link
US (5) US6943249B2 (en)
EP (3) EP2181988B1 (en)
JP (1) JP4792550B2 (en)
AU (2) AU2004222274B2 (en)
BR (1) BRPI0408506A (en)
CA (1) CA2518973A1 (en)
CY (2) CY1114213T1 (en)
DK (2) DK1608634T3 (en)
EC (1) ECSP056023A (en)
ES (2) ES2575535T3 (en)
HU (1) HUE028268T2 (en)
MX (1) MXPA05009969A (en)
PL (2) PL2181988T3 (en)
PT (2) PT2181988E (en)
SI (2) SI1608634T1 (en)
WO (1) WO2004082822A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8902490A (en) * 1989-10-06 1991-05-01 Leonardus Mathijs Marie Nevels METHOD FOR CLEANING FLUE GASES
ATE314768T1 (en) * 2001-10-08 2006-01-15 Cit Alcatel METHOD FOR DISTRIBUTING LOAD BETWEEN SEVERAL COMMON EQUIPMENT IN A COMMUNICATIONS NETWORK AND NETWORK FOR APPLYING THE METHOD
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
WO2008088779A2 (en) * 2007-01-11 2008-07-24 Ivax Pharmaceuticals S.R.O. Solid state forms of 5-azacytidine and processes for preparation thereof
WO2009016617A2 (en) * 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
KR20100102092A (en) * 2007-09-26 2010-09-20 마운트 시나이 스쿨 오브 메디신 Azacytidine analogues and uses thereof
CA2742252A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
BRPI0912717A2 (en) 2008-05-15 2014-12-23 Celgene Corp PHARMACEUTICAL COMPOSITION, AND, USE OF 5-AZACYTIDINE
EP2321302B1 (en) * 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
CA2733591C (en) * 2008-08-08 2016-06-28 Scinopharm Taiwan Ltd. Process for making 5-azacytosine nucleosides and their derivatives
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr Preparation of decitabine
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
JP2014503597A (en) 2011-01-31 2014-02-13 セルジーン コーポレイション Pharmaceutical composition of cytidine analogue and method of use thereof
BR112013025167A2 (en) 2011-03-31 2019-09-24 Celgene Int Sarl process for preparing 5-azacitidine, or a salt, solvate, hydrate, or polymorph thereof, 5-azacitidine, 5-azacitidine salt, or a salt, solvate, hydrate, or polymorph
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
AU2012312308B2 (en) 2011-09-23 2015-11-19 Celgene Corporation Romidepsin and 5-azacitidine for use in treating lymphoma
WO2013049093A1 (en) 2011-09-26 2013-04-04 Celgene Corporation Combination therapy for chemoresistant cancers
KR101987861B1 (en) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Administration of nedd-8 activating enzyme inhibitor and hypomethylating agent
WO2013080221A2 (en) * 2011-12-01 2013-06-06 Hetero Research Foundation Process for alvimopan
US9669048B2 (en) * 2012-10-25 2017-06-06 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
US9765108B2 (en) 2012-11-19 2017-09-19 Shilpa Medicare Limited Formulation of 5-azacytidine
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine
WO2014160698A1 (en) 2013-03-26 2014-10-02 Celgene Corporation SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
CN103450303A (en) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 Azacitidine crystal form A and azacitidine crystal form B as well as preparation method thereof
PL3182996T3 (en) 2014-08-22 2023-04-17 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
BR122024000250A2 (en) 2015-10-15 2024-02-27 Les Laboratoires Servier USE OF A MUTANT ISOCITRATE 1 (IDH1) DEHYDROGENASE INHIBITOR AND A DNA DEMETHYLATING AGENT
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
EP3527226A4 (en) * 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor
CN109988207B (en) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 Preparation method of azacitidine crystal form
CN110642901A (en) * 2019-11-11 2020-01-03 扬子江药业集团有限公司 Azacitidine methanolate, preparation method thereof, pharmaceutical composition and application
WO2022251663A2 (en) * 2021-05-27 2022-12-01 Emory University Novel universal anti-rna virus agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891623A (en) * 1971-05-04 1975-06-24 Schering Ag Process for preparing cytidines
US6723728B2 (en) * 2001-03-01 2004-04-20 Gilead Sciences, Inc. Polymorphic and other crystalline forms cis-FTC

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (en) * 1963-12-22
CH527207A (en) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Process for the preparation of 1-glycosyl-5-azacytosines
CH507969A (en) * 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Process for the preparation of 1-glycosyl-5-azacytosines
DE2012888C3 (en) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Process for the preparation of 5-azapyrimidine nucleosides
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2508312A1 (en) * 1975-02-24 1976-09-02 Schering Ag NEW PROCESS FOR THE PRODUCTION OF NUCLEOSIDES
DE2757365A1 (en) * 1977-12-20 1979-06-21 Schering Ag NEW PROCESS FOR THE PRODUCTION OF NUCLEOSIDES
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
JPH1053576A (en) * 1996-06-07 1998-02-24 Eisai Co Ltd Polymorphic crystal of donepezil hydrochloride and its production
DE69721339T2 (en) 1996-10-16 2004-01-22 Ribapharm, Inc., Costa Mesa MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND THEIR APPLICATIONS
WO2000075143A1 (en) * 1999-06-03 2000-12-14 Eisai Co., Ltd. Crystals of carbapenem derivatives and pharmaceutical preparations for injection
JP4162406B2 (en) * 1999-07-09 2008-10-08 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Novel synthesis method of heteroaryl-substituted urea compounds
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2002020453A1 (en) * 2000-09-07 2002-03-14 Kaneka Corporation Methods for crystallization of hydroxycarboxylic acids
JP2006507255A (en) 2002-09-24 2006-03-02 コローニス ファーマシューティカルズ インコーポレイテッド 1,3,5-triazine for the treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2503150A1 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
EP1517893A2 (en) * 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6877855B2 (en) 2003-07-08 2005-04-12 Dave Ng Spectacles with peripheral lens support
US20070190022A1 (en) 2003-08-29 2007-08-16 Bacopoulos Nicholas G Combination methods of treating cancer
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
WO2008088779A2 (en) 2007-01-11 2008-07-24 Ivax Pharmaceuticals S.R.O. Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en) 2007-01-25 2009-11-11 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
WO2009016617A2 (en) 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
CA2742252A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
BRPI0912717A2 (en) 2008-05-15 2014-12-23 Celgene Corp PHARMACEUTICAL COMPOSITION, AND, USE OF 5-AZACYTIDINE
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
ES2400779T3 (en) 2008-08-06 2013-04-12 Sicor, Inc. Process to prepare an intermediate product of azacitidine
CA2733591C (en) 2008-08-08 2016-06-28 Scinopharm Taiwan Ltd. Process for making 5-azacytosine nucleosides and their derivatives
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (en) 2010-03-30 2013-04-11 Chemi Spa PROCESS FOR THE SYNTHESIS OF AZACITIDINE AND DECITABINE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891623A (en) * 1971-05-04 1975-06-24 Schering Ag Process for preparing cytidines
US6723728B2 (en) * 2001-03-01 2004-04-20 Gilead Sciences, Inc. Polymorphic and other crystalline forms cis-FTC

Also Published As

Publication number Publication date
EP2266965A1 (en) 2010-12-29
EP2181988A1 (en) 2010-05-05
WO2004082822A2 (en) 2004-09-30
EP1608634B1 (en) 2013-05-22
DK2181988T3 (en) 2016-06-06
ES2575535T3 (en) 2016-06-29
HUE028268T2 (en) 2016-12-28
EP2181988B1 (en) 2016-05-11
AU2010241198A1 (en) 2010-11-25
US8211862B2 (en) 2012-07-03
AU2004222274A1 (en) 2004-09-30
ES2425474T3 (en) 2013-10-15
BRPI0408506A (en) 2006-03-14
SI2181988T1 (en) 2016-09-30
US6943249B2 (en) 2005-09-13
AU2004222274B2 (en) 2010-11-04
PT1608634E (en) 2013-08-27
SI1608634T1 (en) 2013-09-30
MXPA05009969A (en) 2006-02-17
US20040186284A1 (en) 2004-09-23
DK1608634T3 (en) 2013-08-12
US20100292180A1 (en) 2010-11-18
PL2181988T3 (en) 2016-11-30
CY1114213T1 (en) 2016-08-31
AU2010241198B2 (en) 2012-05-10
US8975392B2 (en) 2015-03-10
US20130274459A1 (en) 2013-10-17
PT2181988E (en) 2016-06-15
JP2006523210A (en) 2006-10-12
US8481715B2 (en) 2013-07-09
JP4792550B2 (en) 2011-10-12
PL1608634T3 (en) 2013-10-31
US20050272675A1 (en) 2005-12-08
EP1608634A2 (en) 2005-12-28
CA2518973A1 (en) 2004-09-30
EP1608634A4 (en) 2006-03-15
ECSP056023A (en) 2006-01-27
US7700770B2 (en) 2010-04-20
CY1117639T1 (en) 2017-04-26
US20120245342A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2004082619A3 (en) Forms of 5-azacytidine
MXPA05012025A (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors.
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2004074244A3 (en) Pyrimidine compounds
MX2007005221A (en) Ascomycin crystalline forms and preparation thereof.
WO2006069363A3 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
WO2009146218A8 (en) Compounds including an anti-inflammatory pharmacore and methods of use
WO2007009109A3 (en) Antiviral compounds
WO2008083248A3 (en) Cyclopamine analogs
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2006092213A8 (en) Pyrazolylcarboxanilides
MXPA05012026A (en) Azaindole compounds as kinase inhibitors.
WO2004089947A3 (en) Novel compounds having an antibacterial activity
WO2006052568A3 (en) Tgf-beta inhibitors
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2004106293A3 (en) Oxazolyl - and thiazolyl - purine based tricyclic compounds.
WO2005021536A3 (en) Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
WO2007017728A3 (en) Novel heterocyclic compounds
WO2005075467A3 (en) Crystalline forms of zolmitriptan
WO2005005389A3 (en) Malonamide derivatives
TW200420541A (en) Crystalline forms
WO2004050663A3 (en) An improved process for the preparation of cefuroxime sodium
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004222274

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2518973

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009969

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006507211

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004222274

Country of ref document: AU

Date of ref document: 20040316

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004222274

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004721078

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004721078

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408506

Country of ref document: BR